ID
45979
Beschrijving
Principal Investigator: Ellen L. Goode, Mayo Clinic, Rochester, MN, USA MeSH: Cystadenocarcinoma, Serous,Ovarian Neoplasms https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000897 Twenty five patients with early stage carcinoma (Stage I and II) of the ovary were consented for this study. As part of a collaborative agreement with Illumina Inc, Tumor-DNA and patient matched normal DNA from blood underwent whole genome sequencing and microarray genotyping and RNA underwent RNASeq. Tissue also underwent IHC staining for TP53 mutations. The aim of the study was to profile the genomic landscape of these early tumors to discover biomarkers for early detection or subgrouping into different genomic or outcome subgroups. Analyses performed include somatic mutation analysis, RNASeq mutation analysis, LOH analysis, structural variant detection. The current release of this study focusses on 17 patients with serous carcinoma and stage 1 or 2 and with high grade (3 or 4).
Link
Trefwoorden
Versies (1)
- 02-04-24 02-04-24 - Madita Rudolph
Houder van rechten
Ellen L. Goode, Mayo Clinic, Rochester, MN, USA
Geüploaded op
2 april 2024
DOI
Voor een aanvraag inloggen.
Licentie
Creative Commons BY 4.0
Model Commentaren :
Hier kunt u commentaar leveren op het model. U kunt de tekstballonnen bij de itemgroepen en items gebruiken om er specifiek commentaar op te geven.
Itemgroep Commentaren voor :
Item Commentaren voor :
U moet ingelogd zijn om formulieren te downloaden. AUB inloggen of schrijf u gratis in.
dbGaP phs000897 Mayo Clinic and Illumina Collaborative Early Stage Ovarian Cancer (ESOC) Study
Eligibility Criteria
- StudyEvent: SEV1
- Eligibility Criteria
- Subject ID, consent group, subject source, source subject ID, and affection status of participants with ovarian cancer and involved in the "CMayo Clinic and Illumina Collaborative Early Stage Ovarian Cancer (ESOC) Study" project.
- Subject ID, sample ID, and sample use variable obtained from participants with ovarian cancer and involved in the "CMayo Clinic and Illumina Collaborative Early Stage Ovarian Cancer (ESOC) Study" project.
- Subject ID, age, clinical trial, tumor characteristics including ascites status, CA125 measurement, tumor stage and grade, malignancy, tumor morphology, remission, cytology, recurrence, residual tumor, pathological review, tumor site, cause of death, diagnostic, chemotherapy, and surgery of participants with ovarian cancer and involved in the "CMayo Clinic and Illumina Collaborative Early Stage Ovarian Cancer (ESOC) Study" project.
- Sample ID, body site where sample was obtained, analyte type, tumor status, and histological type of sample obtained from participants with ovarian cancer and involved in the "CMayo Clinic and Illumina Collaborative Early Stage Ovarian Cancer (ESOC) Study" project.
Similar models
Eligibility Criteria
- StudyEvent: SEV1
- Eligibility Criteria
- Subject ID, consent group, subject source, source subject ID, and affection status of participants with ovarian cancer and involved in the "CMayo Clinic and Illumina Collaborative Early Stage Ovarian Cancer (ESOC) Study" project.
- Subject ID, sample ID, and sample use variable obtained from participants with ovarian cancer and involved in the "CMayo Clinic and Illumina Collaborative Early Stage Ovarian Cancer (ESOC) Study" project.
- Subject ID, age, clinical trial, tumor characteristics including ascites status, CA125 measurement, tumor stage and grade, malignancy, tumor morphology, remission, cytology, recurrence, residual tumor, pathological review, tumor site, cause of death, diagnostic, chemotherapy, and surgery of participants with ovarian cancer and involved in the "CMayo Clinic and Illumina Collaborative Early Stage Ovarian Cancer (ESOC) Study" project.
- Sample ID, body site where sample was obtained, analyte type, tumor status, and histological type of sample obtained from participants with ovarian cancer and involved in the "CMayo Clinic and Illumina Collaborative Early Stage Ovarian Cancer (ESOC) Study" project.
C0680251 (UMLS CUI [1,2])
C1706256 (UMLS CUI [1,2])
C0029925 (UMLS CUI [1,3])
C0680251 (UMLS CUI [2,1])
C0241889 (UMLS CUI [2,2])
C1511022 (UMLS CUI [2,3])
C1511024 (UMLS CUI [2,4])
C0206530 (UMLS CUI [2,5])
C0006826 (UMLS CUI [1,2])
C0440743 (UMLS CUI [1,3])
C0019638 (UMLS CUI [1,4])